Companies /Healthcare

Rigel Pharmaceuticals

NASDAQ: RIGL Biotechnology
$40.09
▼ $1.10 (−2.67%) today
Markets closed · 9:08pm ET

RIGL at a Glance

Valuation
Market cap
$775.6M
P/E ratio
2.6
Profitability
Revenue (TTM)
$288.2M
Profit margin
106.6%
EPS (TTM)
$16.07
Price
52-week range
$25 – $53
Street target
$64.40

Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: RIGL rigel.com

About Rigel Pharmaceuticals

Rigel Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops and markets therapies for hematologic disorders and cancer. It sells four products in the U.S.:
- **TAVALISSE (fostamatinib):** for chronic immune thrombocytopenia (ITP).
- **REZLIDHIA (olutasidenib):** for relapsed or refractory IDH1-mutated acute myeloid leukemia.
- **GAVRETO (pralsetinib):** for RET fusion-positive non-small cell lung cancer and thyroid cancer.
- **VEPPANU (vepdegestrant):** an oral PROTAC degrader for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, launched in August 2026 after a transfer from Arvinas and Pfizer.

Rigel also earns contract revenues, including royalties, milestones and drug-supply sales, from partners Grifols, Kissei, Medison and Knight Therapeutics, which commercialize fostamatinib outside the U.S. Its lead pipeline asset is R289, a dual IRAK1/4 inhibitor in Phase 1b development for relapsed or refractory lower-risk myelodysplastic syndrome. Updated

RIGL Coverage

Frequently Asked Questions

What does Rigel Pharmaceuticals do?

Rigel Pharmaceuticals is a commercial-stage biotechnology company that discovers, develops and markets therapies for hematologic disorders and cancer.

What is the RIGL stock price target?

The Wall Street consensus 12-month price target for RIGL is $64.40.